Skip Navigation

Annals of Oncology 2009 20(2):200-203; doi:10.1093/annonc/mdp018
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lévy, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lévy, B. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

editorials

Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor

B. I. Lévy

Cardiovascular Research Center, Inserm U689 and Department of Non-Invasive Investigations, Lariboisière Hospital, Paris, France

(E-mail: bernard.levy@inserm.fr)

The first 150 words of the full text of this article appear below.

Arterial hypertension is a commonly reported side-effect in all clinical trials testing all inhibitors of angiogenesis and especially inhibitors of vascular endothelial growth factor (VEGF)/VEGFR-2 signaling [1]. Whatever their initial level of blood pressure, every patient receiving antiangiogenic treatment evidenced rapid and large increases in blood pressure; in most cases, the blood pressure values did not reach the levels characterizing clinical hypertension [2]. In the present issue of the Annals of Oncology, Scartozzi et al. [3] present a clinical trial suggesting that 20% of patients with metastatic colorectal cancer receiving bevacizumab in combination with irinotecan and 5-fluorouracil developed, as expected from previous trials, grades 2–3 hypertension. Most important: partial remission was observed in 75% of these hypertensive patients versus 32% of patients with no hypertension. These authors suggest that bevacizumab-induced hypertension may represent a predictive marker for antiangiogenic treatment efficacy.

This important result . . . [Full Text of this Article]

angiogenesis in health and diseases
arterial hypertension and microcirculation
antiangiogenic treatments and arterial hypertension

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Ravaud and M. Sire
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
Ann. Onc., May 1, 2009; 20(5): 966 - 967.
[Full Text] [PDF]